Key Highlights

  • Acrivon (NASDAQ:ACRV) reported a net loss of USD 17.9 million for the quarter ended September 30, 2026, or USD 0.42 per share, against USD 0.47 a year earlier.
  • The nine-month net loss narrowed to USD 54.9 million from USD 58.9 million, as general and administrative spending fell USD 5.2 million to USD 13.5 million.
  • Cash, cash equivalents and investments stood at USD 77.8 million, which the company says funds operations into the fourth quarter of 2027.
  • Management disclosed substantial doubt about continuing as a going concern, and in November it acquired an oral JAK1 inhibitor, ACR-525, for consideration it called not material.

A Narrower Loss Built on Lower Overhead

Acrivon Therapeutics (NASDAQ:ACRV) filed its Quarterly Report on November 16, 2026, covering the quarter ended September 30, 2026. The clinical-stage oncology company uses its AP3 proteomics platform to match drugs to patients and has no approved product or revenue. Third-quarter operating expenses fell to USD 18.5 million from USD 19.7 million, with Research and Development up to USD 14.5 million from USD 13.6 million and general and administrative costs down to USD 4.0 million from USD 6.0 million. Interest income roughly halved to USD 0.7 million from USD 1.5 million, leaving a net loss of USD 17.9 million. For the nine months the loss was USD 54.9 million, with employee-related expenses, including stock-based compensation, accounting for USD 4.2 million of the overhead saving.

Pipeline Spending Centres on ACR-368

Nine-month research and development spending was USD 43.6 million, with USD 17.6 million directed to the lead program ACR-368, also known as prexasertib, and USD 4.7 million to ACR-2316. ACR-368 is a CHK1 and CHK2 inhibitor in a Phase 2b registrational-intent trial in endometrial cancer, where interim data showed an objective response rate of 39% in one arm. A prespecified interim analysis of the serous endometrial arms is expected in the fourth quarter of 2026. In November 2026 the company also acquired ACR-525, an oral JAK1 inhibitor aimed at eosinophilic esophagitis, plus a preclinical PKCθ program, from Aqilion AB. The report says no further milestone or Royalty payments are owed.

Runway Into 2027 but a Going-Concern Warning

Cash, cash equivalents and investments were USD 77.8 million at September 30, 2026. Management expects that to fund operating and Capital spending into the fourth quarter of 2027, yet it also states the cash is not expected to last beyond 12 months from the filing date, which raises substantial doubt about continuing as a going concern. Operating cash outflow for the nine months was USD 47.8 million, and financing inflow was USD 7.2 million, mostly from an April 2026 at-the-market sale of 4,054,954 shares at USD 1.80 for about USD 7.3 million in gross proceeds. The accumulated Deficit reached USD 329.8 million, and further Equity raises would dilute holders.

Where Things Stand

Acrivon (NASDAQ:ACRV) narrowed its nine-month loss to USD 54.9 million mainly by trimming general and administrative costs by USD 5.2 million, while research spending slipped only USD 1.7 million to USD 43.6 million. The cushion is thinner than the headline cash figure suggests: USD 77.8 million is expected to last into the fourth quarter of 2027, but the filing itself flags substantial doubt about going-concern status. The nearer markers are the fourth-quarter interim data from the serous endometrial arms of ACR-368 and any new financing, which the company says it will need.